PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. - Wikidata - awgldk - TriplyDB

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

http://www.wikidata.org/entity/Q33958963

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Connecting Malfunctioning Glial Cells and Brain Degenerative Disorders Trial watch - inhibiting PARP enzymes for anticancer therapy Evaluating biomarkers to model cancer risk post cosmic ray exposure Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies DNA damage response and prostate cancer: defects, regulation and therapeutic implications Sapacitabine for cancer Contemporary murine models in preclinical astrocytoma drug development Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Therapeutic targeting of cancers with loss of PTEN function.Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic Drugging the addict: non-oncogene addiction as a target for cancer therapy A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines.Glioblastoma biomarkers from bench to bedside: advances and challenges.Does PTEN loss impair DNA double-strand break repair by homologous recombination?Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.Targeting metastatic upper gastrointestinal adenocarcinomas Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.PTEN: Multiple Functions in Human Malignant Tumors Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma.Novel therapies in glioblastoma.Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions Personalized therapy in endometrial cancer: challenges and opportunities.PARP-1 protein expression in glioblastoma multiforme.

P2860

Q21129302-132D5192-87ED-4A2C-9093-1509A3007987 Q26744443-A69C8F11-67AD-4F0C-8217-2EC5182DF2F9 Q26745673-D6B4B3BB-BF3A-4418-986D-07BB4FCFF051 Q26747120-9AE8FF22-D597-4548-9ECB-74050F92F9FD Q26799714-2AA2DD0C-F154-41B6-818B-17E690A3A96E Q26829155-056F0602-4A81-457C-8479-795048ACC1BA Q27024675-12346869-AC28-422E-817B-A8E4FA8B59F4 Q27026937-7A10AF23-FC67-49BC-8F1C-6943350D8E99 Q27851755-17DD9E3D-736F-45E0-A43C-2F443CB99151 Q27852671-0A30850F-3CB1-4DB5-A457-63E1CC91D2EE Q27852764-61C35951-D7BA-40F1-9006-0815742D8689 Q28071541-E0491BEE-60B7-4AF8-B577-AB94D3459697 Q28079559-DF10D70F-1C33-4A05-AE7A-8D1FF4B21B8E Q33415790-F7732B9A-C323-4CCA-B8CC-BC09A2E10816 Q33557916-442016A5-BFD8-4501-A299-72749C65CC76 Q33599105-86DA6C91-1CBB-448B-8786-9E25A0F3A76A Q33618910-273AA315-6F61-47AE-81C3-FEAC5AE6DC08 Q33697447-4D4537C6-B1C9-4736-AB40-531E80EA8104 Q33917630-189F6E73-49DC-4288-A0DA-FE9D2DD1C3BE Q33925330-0B9EA2E3-80A1-4EC8-A4B9-B7D78646EDD9 Q34103890-DC3FB645-41B0-4ED0-B61F-B8512C8E7C08 Q34119182-F3E02A3B-646A-45E3-AC94-956DAC2DC57E Q34516867-48D315C4-0F52-437A-BB9E-01997A02CB1E Q34752116-DCD6EF20-A3AE-4ACB-8F24-961A08FC8C1F Q35000785-15CE035C-CB76-4A73-B9D3-3C64E0520A06 Q35051154-56ABBE8F-9329-4F3E-96E5-C1F676B6A38F Q35051517-B346753D-8DF9-480E-AC1B-2CA47527E9BA Q35087328-26E98F43-DE62-46C6-A966-0F3836E8193C Q35110170-99CF62EF-5287-485F-80D7-56BCF868D975 Q35119267-66B3A7C7-9667-427C-826B-877913CB6506 Q35169608-5D9AC5DD-9ADA-496D-9C3C-87308358EBA0 Q35221471-B2A7DB12-CA3E-49B5-A31F-F4150B04DB6C Q35534509-97E78C4F-792C-43CE-8ABA-9145233415B9 Q35741555-E2802528-08A6-41A7-B092-DDE3115A620F Q35763894-2C72E577-76DD-4CE9-A8D8-27CBB6D5FDE3 Q35788748-4FE183E8-DB5E-4D02-8BC0-886EB776A709 Q35864136-390E27D3-0F76-41E8-8716-3DB455E196A7 Q35869898-BDFAD87F-5E39-4E7A-83E9-F7F287224D5A Q35911350-3223E003-B942-4234-BD4F-22F75643387A Q35959677-C8DC22F0-548F-4F93-AA3C-0C5C71F6F0F6

P2860

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

http://www.wikidata.org/entity/Q33958963

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@ast

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@en

type

label

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@ast

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@en

prefLabel

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@ast

PTEN loss compromises homologo ...... ribose) polymerase inhibitors.

@en

P1433

Q33958963-515EAEF4-B171-4B66-9925-36422B532331

P1476

Q33958963-6342B47D-56FF-49E3-B09D-F78389C70DEF

P2093

Q33958963-1CAA238B-6D6E-4F0D-8896-31239B53316D

Q33958963-26EA4B41-4BFA-44A2-B030-D7A183CD29DA

Q33958963-98C995E3-399B-4966-99E6-83FC14632152

Q33958963-B53889D7-9CFE-4943-9322-7FA666432199

Q33958963-C80E6DBC-5105-4A6A-83D8-C02BAA399927

Q33958963-CFFA8ED7-6C9B-42E7-942D-D0457A1A2C7B

P2860

Q33958963-0B7617B6-0A4F-4CE8-B2C2-42F7A7655056

Q33958963-0E8095BF-CC2D-4D82-8B87-17F2BE1B89E0

Q33958963-0F494C42-D57C-4A5A-97E5-0A42F75CBA0B

Q33958963-19E88DA3-0F1F-4725-9D18-292F689A6022

Q33958963-1C930E6C-9A88-4D9D-B350-8E4534B86D45

Q33958963-1F35100B-4FE8-4032-A8F3-DCC9A64FF0FF

Q33958963-2EAA62AA-47EC-4B7C-A4A4-315F144F49F1

Q33958963-35AF50B9-CDC0-4BA9-9FEB-D9F5479F6E29

Q33958963-47AE93D5-2126-4925-81B1-8D522B98406E

Q33958963-484B3C2E-719F-4ED8-8B83-DC31449D1242

P304

Q33958963-ACD2B230-2AFB-4155-88DA-3C6CBD56ECFC

P31

Q33958963-F42A2747-A10D-4547-A228-016C60C2AEFB

P356

Q33958963-C2A93986-2530-4C1A-A3DA-8A418652ABFD

P407

Q33958963-F379A80D-283D-45ED-99F3-66EF934AC9C6

P433

Q33958963-ADF28E77-3BFB-4168-BF2C-FF574EA1A7DA

P478

Q33958963-962E617F-C23C-4834-B4B8-6E340A6D3A57

P50

Q33958963-A53BC027-7E70-4E42-9194-D90D2CAA0A80

P577

Q33958963-885F4258-17DC-4482-BADA-FF5EAD187DEA

P5875

Q33958963-A97C910B-F163-499F-9378-3660AA953BBD

P698

Q33958963-F145E5EC-D5C7-4E71-83C4-E8E028F52619

P921

Q33958963-77c92693-340b-47d3-9098-713ef2f036fc

P932

Q33958963-A346AF75-A497-45E0-9620-98598EB8480B

P356

0008-5472.CAN-09-4295

P1433

Cancer Research

P1476

PTEN loss compromises homologo ...... -ribose) polymerase inhibitors

@en

P2093

Bipasha Mukherjee

http://www.w3.org/2001/XMLSchema#string

Brandon Hahm

http://www.w3.org/2001/XMLSchema#string

Brian McEllin

http://www.w3.org/2001/XMLSchema#string

Nozomi Tomimatsu

http://www.w3.org/2001/XMLSchema#string

Robert M Bachoo

http://www.w3.org/2001/XMLSchema#string

Sandeep Burma

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

H2AX: the histone guardian of the genome

Essential role for nuclear PTEN in maintaining chromosomal integrity

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

P304

5457-5464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-4295

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Cristel V Camacho

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44656396

http://www.w3.org/2001/XMLSchema#string

P698

20530668

http://www.w3.org/2001/XMLSchema#string

P921

P932

2896430

http://www.w3.org/2001/XMLSchema#string